PUBLIC UNIV CORPORATION NARA MEDICAL UNIV has a total of 24 patent applications. It increased the IP activity by 125.0%. Its first patent ever was published in 2013. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are DIAGENICS INTERNAT CORP, CANTOR THOMAS L and BARNIKOL WOLFGANG.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 7 | |
#2 | EPO (European Patent Office) | 6 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | China | 2 | |
#5 | Republic of Korea | 2 | |
#6 | Taiwan | 2 | |
#7 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Medical technology | |
#5 | Chemical engineering |
# | Name | Total Patents |
---|---|---|
#1 | Nogami Keiji | 13 |
#2 | Shima Midori | 13 |
#3 | Ogiwara Kenichi | 6 |
#4 | Kitazawa Takehisa | 5 |
#5 | Soeda Tetsuhiro | 5 |
#6 | Nakanishi Yasuaki | 4 |
#7 | Ueda Tomohiro | 3 |
#8 | Torimoto Kazumasa | 3 |
#9 | Matsumoto Tomoko | 3 |
#10 | Tabuchi Yuka | 2 |
Publication | Filing date | Title |
---|---|---|
WO2020137172A1 | Method for diagnosing interstitial cystitis | |
EP3799798A1 | Transplantation tendon extractor | |
TW201836636A | Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii | |
US2019076507A1 | Artificial Red Blood Cell Having Ability to Inhibit Conversion of Hemoglobin into Methemoglobin | |
EP3287791A1 | Method for evaluating coagulation ability of blood specimen, and reagent, reagent kit and device to be used therein |